AstraZeneca's Phase III trial for its drug Wainua failed to meet its primary endpoint, causing a 9% drop in its shares and pulling the FTSE 100 into negative territory. The trial aimed to treat a rare heart disease but showed no significant benefit over placebo. Meanwhile, Computacenter's shares jumped over 13% following a strong trading update, and miners like Antofagasta, Anglo American, and Glencore rose by more than 3%. Other market news includes Capita lowering profit forecasts due to pension issues and Seraphim Space's portfolio sale being valued lower than expected due to share price declines. The National Energy System Operator warned of tight electricity margins amid a European heatwave but assured no supply risk.
The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks ...
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit...
AstraZeneca's shares fell 9.55%, wiping £19 billion off its value, after its Wainua drug failed a major Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial did not meet its primary goal of reducing cardiovascular de...
AstraZeneca's shares fell nearly 9% after its experimental heart drug, Wainua, failed to meet the primary goal in a late-stage trial. The drug aimed to reduce deaths and heart-related emergencies over 140 weeks for patients with a rare heart conditio...
